Biomarkers in Cancer Patients at Risk for Venous Thromboembolism: Data from the AVERT Study
Posted by Adam Awdish on
Human tPA 85% Single Chain Purified from Innovative Research was used in the following study:
Biomarkers in Cancer Patients at Risk for Venous Thromboembolism: Data from the AVERT Study
Anton Ilich, Vaibhav Kumara, Michael Henderson, Ranjeeta Mallick, Philip Wells, Marc Carrier, Nigel S. Key
Elsevier Ltd.
July 28, 2020
Currently, cancer-associated venous thromboembolism (VTE) and the ways it can develop are not well characterized. Scientists know that the risk of VTE varies depending on the type of cancer, however, the various mechanisms surrounding VTE are not thoroughly understood.
In a study published this Summer, researchers selected several biomarkers that may signal possible mechanisms of venous thrombosis in a variety of tumor types in AVERT study participants. AVERT, a randomized placebo controlled thromboprophylaxis study in ambulatory cancer patients, provides a unique opportunity to gain insights into thrombotic mechanisms.
The researchers included 449 AVERT participants in their study, and they found that baseline expression of the selected thrombosis biomarkers differed significantly by individual tumor type when compared to normal control samples. These early findings suggest that baseline activation of various pathways may vary significantly by tumor type and disease stage.
Related products available from Innovative Research also include:
Human tPA 95% Two Chain Purified